Press "Enter" to skip to content

Alembic Pharmaceuticals gets USFDA nod for ophthalmic solution

The company has received approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) Olopatadine Hydrochloride ophthalmic solution USP, 0.1 per cent, Alembic Pharmaceuticals said in a filing to BSE.
onjunctivitis.

Original source: https://health.economictimes.indiatimes.com/news/pharma/alembic-pharmaceuticals-gets-usfda-nod-for-ophthalmic-solution/67021064?utm_source=RSS&utm_medium=ETRSS